Desmoid tumor (TD). It is a locally invasive benign soft tissue tumor associated with a high recurrence rate but without metastatic potential.
Summary
[ hide ]
- 1 Epidemiology
- 2 Clinical description
- 3 Etiology
- 4 Diagnostic methods
- 1 Differential diagnosis
- 5 Genetic advice
- 6 Management and treatment
- 7 Forecast
- 8 Sources
epidemiology
TDs are responsible for less than 3% of soft tissue tumors. Its annual incidence is estimated between 1 / 250,000 and 1 / 500,000. They preferably affect women and can occur between 15 and 60 years of age, although more frequently during early adolescence and with a peak of age towards 30 years.
Clinical description
In principle, TDs can appear in any part of the body: extra-abdominal ( neck , shoulders, upper limbs, gluteal region), abdominal (originating in the muscular fascia or in the abdominal / thoracic wall) and, more rarely, intra-abdominal in the mesentery or retroperitoneum. They are usually discovered as firm, smooth palpable masses. Depending on the location of the tumor, symptoms may include pain, fever, functional disability, or loss of function of the affected organ. TDs can appear after surgical resection, typically after cesarean section . Intra-abdominal TDs are commonly seen in patients with an association of familial adenomatous polyposis (FAP) or Gardner syndrome.
Etiology
TDs are the result of the proliferation of well-differentiated myofibroblasts. The exact etiopathogenic mechanism is still unknown, but it seems to have a multifactorial origin in which genetic and hormonal factors would be involved. Somatic mutations in the CTNNB1 (3q21) gene encoding beta-catenin have been found in about 85% of sporadic cases. In cases with PAF, TDs have been associated with mutations in the APC tumor suppressor gene (5q21-q22) that encodes the colon adenomatous polyposis protein.
Diagnostic methods
The initial diagnosis is based on imaging techniques (computed tomography and magnetic resonance imaging) that reveal the presence of a growing infiltrating mass. This diagnosis is confirmed by a biopsy of the tumor showing abundant collagen surrounding the elongated spindle cells with small, regular nuclei and clear cytoplasm . Immunohistological examination shows the expression of muscle markers (actin, desmin, vimentin) and the absence of CD34. Additionally, the diagnosis can be confirmed by detecting mutations in CTNNB1.
Differential diagnosis
The differential diagnosis is wide and ranges from fibrosarcoma on the one hand to myofibroblastic processes such as nodular fasciitis or even hypertrophic and keloidal scars on the other. The differential diagnosis of intra-abdominal TD includes gastrointestinal stromal tumors, solitary fibrous tumors, inflammatory myofibroblastic tumors, sclerosing mesenteritis, and retroperitoneal fibrosis.
Genetic advice
Most of the cases are sporadic. Family cases (5-10%) are associated with PAF.
Management and treatment
Complete surgical resection remains the therapeutic basis for TD. For unresectable tumors, those not candidates for surgical resection with free margins (R0 resection) or those accompanied by unacceptable functional loss, non-surgical treatments include radiotherapy, antiestrogenic therapy, non-steroidal anti-inflammatory agents, chemotherapy (eg methotrexate, vinblastine / vinorelbine, pegylated liposomal doxorubicin) and / or tyrosine kinase inhibitors (eg imatinib, sorafenib). TDs have a variable and often unpredictable clinical evolution, so a watchful waiting period is recommended in asymptomatic patients. Since TDs often recur, it is essential to carry out a follow-up strategy every 3-6 months.
Forecast
Local recurrence occurs in about 70% of cases. The prognosis depends on the type of tumor . Life expectancy is normal for abdominal and extra-abdominal tumors. However, it is lower in cases of intra-abdominal TD due to complications such as intestinal obstruction, hydronephrosis or sepsis. Repeated surgical resections carry an increased risk of morbidity.
